Zidovudine-induced pure red cell aplasia presenting after 4 years of therapy [3]

AIDS

Volumn 19, Issue 17, 2005, Pages 2046-2047

  Weinkove, Robert ^a   Rangarajan, Savita ^a   Van Der Walt, Jon ^a   Kulasegaram, Ranjababu ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; ZIDOVUDINE;

ANAMNESIS; BONE MARROW BIOPSY; CLINICAL FEATURE; CYTOPATHOLOGY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; ERYTHROCYTE COUNT; HEMOPHILIA A; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LETTER; MEDICAL EXAMINATION; PRIORITY JOURNAL; PURE RED CELL ANEMIA; STEVENS JOHNSON SYNDROME;

EID: 27944507331     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000191230.60008.69     Document Type: Letter

References (2)

1. Cohen H, Williams I, Matthey F, Miller RF, Machin SJ, Weller IV. Reversible zidovudine-induced pure red-cell aplasia. AIDS 1989; 3:177-178.
2. Majluf-Cruz A, Luna-Castaños G, Treviño-Pérez S, Santoscoy M, Nieto-Cisneros L. Lamivudine-induced pure red cell aplasia. Am J Hematol 2000; 65:189-191.